荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688331 荣昌生物

盘后交易 11-19 15:00:01

{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":32.34,"timestamp":1731999601000,"preClose":31.87,"halted":0,"volume":3254828,"delay":0,"floatShares":162000000,"shares":544000000,"eps":-2.8514,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.47,"latestTime":"11-19 15:00:01","open":32.09,"high":32.56,"low":31.08,"amount":103000000,"amplitude":0.0464,"askPrice":32.35,"askSize":4,"bidPrice":32.34,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.8514,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":31.87,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":35.06,"lowLimit":28.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":544332083,"pbRate":7.43,"roa":"--","roe":"--","epsLYR":-2.8,"committee":0.435294,"marketValue":17604000000,"floatMarketCap":5237000000,"peRate":-11.341797,"changeRate":0.0147,"turnoverRate":0.0201,"status":0,"afterMarket":{"amount":0,"volume":0,"close":32.34,"buyVolume":0,"sellVolume":0,"time":1732000742464,"indexStatus":"盘后交易 11-19 15:19:02","preClose":31.87}},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2484618824","title":"荣昌生物(09995)下跌5.13%，报16.26元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484618824","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484618824?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:10","pubTimestamp":1731910220,"startTime":"0","endTime":"0","summary":"11月18日，荣昌生物(09995)盘中下跌5.13%，截至14:10，报16.26元/股，成交1974.22万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18141045391699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","09995","LU1064130708.USD","BK1574","688331","BK0239","LU1064131003.USD","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2483363346","title":"荣昌生物公布马兰拟辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483363346","media":"新浪港股","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483363346?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:23","pubTimestamp":1731630180,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　荣昌生物（09995）发布公告，公司董事会近日收到独立非执行董事马兰博士的书面辞呈。马兰博士根据中国科学院院士兼职管理的相关规定，提出辞去董事会独立非执行董事及提名委员会、战略委员会委员职务。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxs6538029.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxs6538029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688331","LU1969619763.USD","BK0239","LU2148510915.USD","LU1064131003.USD","LU2328871848.SGD","BK1161","BK1583","BK1574","LU1064130708.USD","09995"],"gpt_icon":0},{"id":"2483122879","title":"荣昌生物(09995)：马兰拟辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483122879","media":"智通财经","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483122879?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:15","pubTimestamp":1731586532,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，公司董事会近日收到独立非执行董事马兰博士的书面辞呈。马兰博士根据中国科学院院士兼职管理的相关规定，提出辞去董事会独立非执行董事及提名委员会、战略委员会委员职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU1064130708.USD","LU2148510915.USD","688331","BK0239","09995","BK1583","LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2483840538","title":"荣昌生物最新公告：独立董事马兰辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2483840538","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483840538?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:52","pubTimestamp":1731574362,"startTime":"0","endTime":"0","summary":"荣昌生物公告称，董事会近日收到独立董事马兰的书面辞职报告。马兰因根据中国科学院院士兼职管理的相关规定，申请辞去公司第二届董事会独立董事及提名委员会、战略委员会委员职务。辞职后，马兰将不再担任公司任何职务。其辞职报告将在新的独立董事到任之日或者独立董事人数不少于公司董事会人数的三分之一起生效。在此之前，马兰仍将按照有关法律法规和《公司章程》的规定继续履行职责。公司将按照相关规定，尽快完成新任独立董事的补选工作。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400027173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1583","LU2328871848.SGD","BK0239","BK1574","BK1161","09995","LU1969619763.USD","LU1064130708.USD","688331","LU1064131003.USD"],"gpt_icon":0},{"id":"2483406708","title":"荣昌生物：关于独立董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2483406708","media":"新浪财经-鹰眼工作室","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483406708?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:40","pubTimestamp":1731573600,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司关于独立董事辞职的公告本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。荣昌生物制药（烟台）股份有限公司董事会近日收到独立董事马兰女士的书面辞职报告。辞职后，马兰女士将不再担任公司任何职务。公司将按照相关规定，尽快完成新任独立董事的补选工作。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-14/doc-incvzmwk7182463.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-14/doc-incvzmwk7182463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09995","LU1064131003.USD","688331","LU1064130708.USD","BK1583","LU2148510915.USD","BK1161","BK0239","BK1574","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2483684277","title":"荣昌生物独立董事马兰辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2483684277","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483684277?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:32","pubTimestamp":1731573120,"startTime":"0","endTime":"0","summary":"财中社11月14日电荣昌生物（688331/09995）发布关于独立董事辞职的公告。独立董事马兰因根据中国科学院院士兼职管理的相关规定，申请辞去公司第二届董事会独立董事及相关委员会职务。辞职后，马兰将不再担任公司任何职务。由于马兰的辞职将导致公司独立董事人数少于董事会成员的三分之一，其辞职报告将在新的独立董事到任之日或独立董事人数恢复到不少于董事会人数的三分之一时生效。在此之前，马兰将继续履行职责。公司将尽快完成新任独立董事的补选工作。2024年前三季度，荣昌生物实现收入12.09亿元，归母净利润-10.71亿元。（文章来源：财中社）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114163408a236d226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114163408a236d226&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688331","LU1969619763.USD","BK1161","BK1583","BK1574","09995","LU2328871848.SGD"],"gpt_icon":0},{"id":"2483016890","title":"荣昌生物(09995)股价下跌8.088%，现价港币$17.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2483016890","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483016890?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:35","pubTimestamp":1731465300,"startTime":"0","endTime":"0","summary":"[下跌股]荣昌生物(09995) 股价在上午10:35比前收市价下跌8.088%，现股价为港币$17.5。至目前为止，今日最高价为$18.94，而最低价为$17.5。总成交量为106.6万股，总成交金额为港币$1.926千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2411131151/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1064131003.USD","BK1161","LU2328871848.SGD","BK1583","LU1969619763.USD","LU2148510915.USD","09995","688331","BK1574","LU1064130708.USD","BK0239"],"gpt_icon":0},{"id":"2483163410","title":"荣昌生物大跌5.08% 获主力净流出881万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483163410","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483163410?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:25","pubTimestamp":1731464747,"startTime":"0","endTime":"0","summary":"11月13日，荣昌生物股价大幅下跌，截至10点25分，荣昌生物下跌5.08%，报34.39元/股，成交8064万元，换手率1.41%，振幅6.04%。资金动向截止发稿，荣昌生物获得主力净流出881万元，其中超大单流出624万元，大单流出256万元。数据显示，该股今日净流入较近5日净流入均值减少509万元。最新财报显示，今年三季报，荣昌生物实现营业收入12.09亿元，同比增长57.10%，净利润为-10.71亿元，同比减少3.96%，基本每股收益为-1.99元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113102604abbba5f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113102604abbba5f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0239","688331"],"gpt_icon":0},{"id":"2483018187","title":"荣昌生物(09995)下跌5.04%，报18.08元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483018187","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483018187?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:11","pubTimestamp":1731463867,"startTime":"0","endTime":"0","summary":"11月13日，荣昌生物(09995)盘中下跌5.04%，截至10:11，报18.08元/股，成交680.39万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13101145231191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","09995","LU2328871848.SGD","688331","LU1064130708.USD","BK0239","LU1064131003.USD","BK1161","LU1969619763.USD","BK1574","BK1583"],"gpt_icon":0},{"id":"2483042989","title":"荣昌生物：亏损缩窄趋势明显 RC18海外临床顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2483042989","media":"长江证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483042989?lang=zh_cn&edition=full","pubTime":"2024-11-13 00:00","pubTimestamp":1731427200,"startTime":"0","endTime":"0","summary":"事件评论前三季度营收同比增长57%，单季度亏损缩窄趋势明显。RC18 针对重症肌无力适应症上市申请获得受理，海外临床顺利推进。RC18 海外针对SLE 的第二项III 期临床已开始筛选病人，近期有望实现首例患者入组；针对MG 的全球多中心III 期临床近期已经FPI，目前正持续入组中。此外，RC48 海外2L UC 和1L UC 两个关键或者III 期临床均持续入组中。RC28 针对DME 适应症III 期已经完成入组，预计2025 年中递交上市申请；wAMD 适应症国内III 期临床预计2024Q4 入组结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111314212395be201f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111314212395be201f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064131003.USD","LU1064130708.USD","688331","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2482273207","title":"【券商聚焦】中信建投维持荣昌生物(09995)“买入”评级 指其三季度增长符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2482273207","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482273207?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:30","pubTimestamp":1731310205,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，2024三季度，荣昌生物 核心产品销售持续放量，单季度收入4.67亿元，同比增长57.10%，符合预期。同时公司三季度归母净亏损3.04亿元，环比缩窄1.44亿元。公司核心产品泰它西普与维迪西妥单抗覆盖自免与肿瘤领域，两款产品的临床研发与商业化推进均在稳步推进状态。但由于公司受到行业变化的影响，该行预计2024-2026年，公司收入分别为15.50亿元、24.53亿元、31.73亿元，维持“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"2482226368","title":"荣昌生物(09995)上涨5.48%，报19.64元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482226368","media":"金融界","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482226368?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:15","pubTimestamp":1731302117,"startTime":"0","endTime":"0","summary":"11月11日，荣昌生物(09995)盘中上涨5.48%，截至13:15，报19.64元/股，成交2270.25万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/11131545138469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688331","LU1969619763.USD","BK0239","LU2148510915.USD","LU1064131003.USD","LU2328871848.SGD","BK1161","BK1583","BK1574","LU1064130708.USD","09995"],"gpt_icon":0},{"id":"2482122581","title":"荣昌生物大幅上涨 获融资净买入236万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482122581","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482122581?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:13","pubTimestamp":1731302019,"startTime":"0","endTime":"0","summary":"11月11日，荣昌生物股价大幅上涨，截至13点13分，荣昌生物上涨5.26%，报37.00元/股，成交1.10亿元，换手率1.91%，振幅6.88%。资金动向截止发稿，荣昌生物获得主力净流出482万元，其中超大单流出315万元，大单流出166万元。融资融券方面，荣昌生物11月08日获得融资净买入236万元，当日该股融资余额为7378万元，当较前一日增加3.31%，实现5连增；该股融券余额为227万元，融券余量为6.16万股，比上日减少0.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111131357a22b4235&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111131357a22b4235&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU1064130708.USD","688331","LU1064131003.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2481172337","title":"荣昌生物：泰它西普用于IgA肾病的Ⅲ期临床入组已完成，目前正在用药随访中","url":"https://stock-news.laohu8.com/highlight/detail?id=2481172337","media":"每日经济新闻","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481172337?lang=zh_cn&edition=full","pubTime":"2024-11-08 20:49","pubTimestamp":1731070156,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：据报导:泰它西普用于 IgA 肾病的 Ⅲ 期临床入组已完成,该研究用药方案分为 A 阶段和 B 阶段，A 阶段是为了验证泰它西普缓解患者蛋白尿方面的有效性以及安全性，B 阶段则验证泰它西普给患者带来的长期肾脏受益。请问在 A 阶段研究完成并达到预设阶段终点时, 可以进行 NDA 吗? 谢谢!荣昌生物（688331.SH）11月8日在投资者互动平台表示，泰它西普用于IgA肾病的Ⅲ期临床入组已完成，目前正在用药随访中，公司将与CDE保持沟通，争取尽早实现新适应症申报。(记者 蔡鼎)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108204955a2248728&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108204955a2248728&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU1064130708.USD","LU1064131003.USD","688331","LU2148510915.USD"],"gpt_icon":0},{"id":"2481426198","title":"荣昌生物大幅上涨 获融资净买入771万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481426198","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481426198?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:02","pubTimestamp":1731034920,"startTime":"0","endTime":"0","summary":"11月08日，荣昌生物股价大幅上涨，截至11点02分，荣昌生物上涨5.00%，报37.20元/股，成交1.37亿元，换手率2.35%，振幅5.64%。资金动向截止发稿，荣昌生物获得主力净流出779万元，其中超大单流出747万元，大单流出30万元。融资融券方面，荣昌生物11月06日获得融资净买入771万元，当日该股融资余额为6653万元，当较前一日增加13.12%，实现3连增；该股融券余额为228万元，融券余量为6.15万股，比上日增加3.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108110213ababea2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108110213ababea2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","688331","BK0239"],"gpt_icon":0},{"id":"2481599162","title":"荣昌生物(09995)上涨5.09%，报19.42元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481599162","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481599162?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:33","pubTimestamp":1731033186,"startTime":"0","endTime":"0","summary":"11月8日，荣昌生物(09995)盘中上涨5.09%，截至10:33，报19.42元/股，成交1579.29万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/08103345068274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK1583","LU2328871848.SGD","LU1969619763.USD","BK0239","LU1064131003.USD","LU2148510915.USD","BK1574","09995","688331","LU1064130708.USD"],"gpt_icon":0},{"id":"2481945179","title":"荣昌生物(09995)下跌5.49%，报18.24元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481945179","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481945179?lang=zh_cn&edition=full","pubTime":"2024-11-07 09:40","pubTimestamp":1730943627,"startTime":"0","endTime":"0","summary":"11月7日，荣昌生物(09995)盘中下跌5.49%，截至09:40，报18.24元/股，成交637.53万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/07094045022510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064131003.USD","BK0239","LU1969619763.USD","LU1064130708.USD","BK1583","LU2148510915.USD","LU2328871848.SGD","688331","09995","BK1574","BK1161"],"gpt_icon":0},{"id":"2481396019","title":"【机构调研记录】湘财基金调研荣昌生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2481396019","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481396019?lang=zh_cn&edition=full","pubTime":"2024-11-07 08:04","pubTimestamp":1730937875,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月6日披露的机构调研信息，湘财基金近期对1家上市公司进行了调研，相关名单如下：1）荣昌生物 个股亮点：H股:荣昌生物于2020-11-09上市；公司研发的泰它西普，是注射用重组B淋巴细胞刺激因子/增殖诱导配体双靶点的新型融合蛋白产品。湘财基金成立于2018年，截至目前，资产管理规模65.16亿元，排名152/207；资产管理规模63.16亿元，排名136/207；管理公募基金数37只，排名115/207；旗下公募基金经理9人，排名119/207。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700006775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0239","09995","BK1161","LU2328871848.SGD","BK1574","LU2148510915.USD","BK1583","LU1064131003.USD","688331","LU1064130708.USD"],"gpt_icon":0},{"id":"2481960113","title":"【机构调研记录】朱雀基金调研荣昌生物、生益电子","url":"https://stock-news.laohu8.com/highlight/detail?id=2481960113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481960113?lang=zh_cn&edition=full","pubTime":"2024-11-07 08:04","pubTimestamp":1730937863,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月6日披露的机构调研信息，朱雀基金近期对2家上市公司进行了调研，相关名单如下：1）荣昌生物 个股亮点：H股:荣昌生物于2020-11-09上市；公司研发的泰它西普，是注射用重组B淋巴细胞刺激因子/增殖诱导配体双靶点的新型融合蛋白产品。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700006758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688183","LU1064131003.USD","BK0214","BK0239","09995","BK1574","LU1969619763.USD","688331","LU1064130708.USD","LU2148510915.USD","BK1161","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2481609342","title":"东海证券：给予荣昌生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481609342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481609342?lang=zh_cn&edition=full","pubTime":"2024-11-06 21:10","pubTimestamp":1730898636,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,伍可心近期对荣昌生物进行研究并发布了研究报告《公司简评报告：收入持续快速增长，经营效率提升》，本报告对荣昌生物给出买入评级，当前股价为36.15元。　　荣昌生物　　投资要点　　收入快速增长，毛利率显著提升。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级1家，中性评级1家；过去90天内机构目标均价为46.76。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600037382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","161027","688331"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","stockEarnings":[{"period":"1week","weight":-0.1295},{"period":"1month","weight":0.0208},{"period":"3month","weight":0.2291},{"period":"6month","weight":-0.3582},{"period":"1year","weight":-0.5052},{"period":"ytd","weight":-0.4865}],"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","perCapita":"21325股","boardName":"医药制造业","registeredCapital":"54433万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　荣昌生物制药(烟台)股份有限公司是一家具有全球化视野的创新型生物制药企业，自成立以来一直专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。公司主营业务是发现、开发与商业化创新、有特色的同类首创（first-in-class）与同类最佳（best-in-class）生物药，以创造药物临床价值为导向，为自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域提供安全、有效、可及的临床解决方案，以满足大量尚未被满足的临床需求。公司的核心产品为泰它西普、维迪西妥单抗、RC28。","serverTime":1732000743151,"listedPrice":48,"stockholders":"7594人(较上一季度增加46.24%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}